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The bile acid deoxycholic acid has a non-linear dose response for DNA damage
and possibly NF-kB activation in oesophageal cells, with a mechanism of action
involving ROS
G. J. S. Jenkins*, J. Cronin, A. Alhamdani1, N. Rawat1,
F. D’Souza1, T. Thomas, Z. Eltahir, A. P. Griffiths2 and
J. N. Baxter1
Institute of Life Science, Swansea School of Medicine, Swansea University,
Swansea SA2 8PP, UK, 1Department of Surgery and 2Department of
Histopathology, Morriston Hospital, Swansea SA6 6NL, UK
Deoxycholic acid (DCA) is a secondary bile acid implicated
in various cancers of the gastrointestinal (GI) tract. In
oesophageal adenocarcinoma, DCA is believed to contrib-
ute to carcinogenesis during reflux where stomach contents
enter the lower oesophagus. It is imperative that we
understand the mechanisms whereby oesophageal carci-
nogens function in order that therapeutic options may be
developed. We have previously shown that DCA can
damage chromosomes and does so through its generation
of reactive oxygen species (ROS). We show here, after
detailed experiments, that DCA appears to have a non-
linear dose response for DNA damage. DCA induces DNA
damage (as measured by the micronucleus assay) at doses
of 100 mM and higher in oesophageal OE33 cells, but fails
to induce such DNA damage below this cut-off dose. We
also show that in terms of NF-kB activation (as measured
by up-regulation of two NF-kB target genes) by DCA,
a similar dose response is observed. This dose–response
data may be important clinically as DCA exposure to the
oesophagus may be used as a way to identify the 10% of
Barrett’s oesophagus patients currently progressing to
cancer from the 90% of patients who do not progress. Only
quantitative studies measuring DCA concentrations in
refluxates correlated with histological progression will
answer this question. We further show here that ROS are
behind DCAs ability to activate NF-kB as antioxidants
(epigallocatechin gallate, resveratrol and vitamin C)
abrogate DCAs ability to up-regulate NF-kB-controlled
genes. In conclusion, low doses of DCA appear to be less
biologically significant in vitro. If this were to be confirmed
in vivo, it might suggest that reflux patients with low DCA
concentrations may be at a lower risk of cancer pro-
gression compared to patients with high levels of DCA in
their refluxate. Either way, antioxidant supplementation
may possibly help prevent the deleterious effects of DCA in
the whole GI tract.
Introduction
Oesophageal adenocarinoma (OA) is an extremely aggressive
form of cancer which is increasing in incidence in the West.
OA is caused by chronic gastro-oesophageal reflux disease
(GORD) whereby stomach acids (and bile) are regularly
regurgitated into the lower oesophagus. GORD affects up to
20–30% of the general population and 10% of these (i.e.
1–2% of the general population) acquire a metaplastic pre-
malignant condition known as Barrett’s oesophagus (BO) (1–3).
Initially, it was thought that the acid component of the refluxate
played the most significant role in the development of BO and its
sequelae, adenocarcinoma. This led to the development of acid-
suppressing drugs to minimize acid reflux with a view to
eliminating symptoms and preventing carcinogenesis in the
lower oesophagus of GORD patients. While acid suppression
therapies are extremely effective at managing symptoms of
GORD, there is little evidence that they have had an impact on
trends in incidence of Barrett’s oesophagus or OA (4,5). This has
led to the theory that some non-acid constituent of reflux, such as
bile, may be driving carcinogenesis.
Over the past 20 years, there have been many animal studies
which have strengthened the link between bile acids and OA.
This work has been invaluable in unpicking the relative
contributions of acid and bile reflux to oesophageal damage
and carcinogenesis. A lot of this work is summarized in a paper
by Marshall et al. (6) and concludes that bile acid reflux
generally worsens the oesophageal damage induced by acid
reflux alone. Further studies have shown, through elegant
surgical models, that bile acids promote OA development,
perhaps even more so, than stomach acid alone (7,8)
As only10% of patients with Barrett’s oesophagus progress
to OA (9), there has been considerable effort recently to try and
identify biomarkers which correctly stratify the ‘progressors’
from the ‘non-progressors’. It is possible that the type and
concentration of bile acid in the refluxate of these patients
may be a useful biomarker. The more damaging secondary bile
acids (particularly in their unconjugated form) are generally
thought to be more closely linked to OA development than their
primary bile acid counterparts. The presence of these kinds
of secondary bile acids in the oesophagus of patients with
GORD has been known for some time (10–12). Table I shows
the range of concentrations of deoxycholic acid (DCA), an
injurious secondary bile acid linked to carcinogenesis, found in
the upper gastrointestinal (GI) tract.
To support the labelling of bile acids like DCA, as
carcinogens in their own right, there has been much evidence
in recent years that such bile acids are capable of inducing
molecular changes consistent with a pro-carcinogenic role. As
well as the accumulating clinical evidence, there is good
experimental data that they are capable of inducing DNA
damage (13,14) and activating oncogenic signalling pathways
(15–17). It is likely that bile acids cause these effects through
their ability to induce intracellular reactive oxygen species
(ROS) (14,18–20). Bile acid induction of oxidative stress is
thought to be linked to their membrane-damaging role (as
detergents). Mitochondrial membrane damage may well lead
directly to increased ROS leakage into the cytoplasm (21).
Therefore, the investigation of the role of ROS in the
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pathogenesis of Barrett’s oesophagus (and OA) and the
potential role of antioxidants in blocking these processes are
fertile areas of research.
We have recently shown that the bile acid DCA is
a clastogen, a mutagen (14) and can activate the pro-
carcinogenic signalling molecule NF-jB (17). Indeed, of all
the bile acids implicated in GI tract cancer, DCA appears to be
a prime candidate carcinogen as it appears to be particularly
bioactive. Our in vitro data support a role for DCA in particular
as other bile acids (including the conjugated forms of DCA) do
not induce similar molecular abnormalities. However, in terms
of assessing individual candidate carcinogens for their ability
to induce molecular defects, it is important to consider the
effect of dose. We have shown recently that classic DNA-
damaging agents and known carcinogens can display non-
linear dose responses for DNA damage induction (22). Hence,
at low doses, these carcinogens do not induce biologically
relevant genetic changes. These non-linear effects are often
described as ‘thresholded’ as they tend to consist of a ‘no effect
level’ at low doses where no increase in DNA damage is seen
above background. This is followed by a key point of inflexion
whereafter subsequent dose-dependent increases in DNA
damage are seen. The determination of the critical dose range
where this transition takes place is essential if one wants to use
this data to set safe human exposure levels. Finally, in order to
complete the picture, as well as the dose response, the
mechanism of action (MOA) responsible for the non-linear
(thresholded) response is often required in order to convince
the scientific community of the plausibility of the effect.
Given the role of bile acids (like DCA) in OA development,
it is essential to understand the critical dose range whereby
DCA is capable of inducing molecular abnormalities consistent
with a pro-carcinogenic effect. Table I shows the known
concentrations of DCA in the upper GI tract and displays the
wide range of values seen in different patients (range 0 lM–
282 lM) (11,23,24). At present, it is not known if variations in
DCA concentration in vivo are involved in modulating the risks
of OA development in individual patients. In terms of
carcinogenic bile acids, we have strived here to assess if the
carcinogenic bile acid DCA has a non-linear dose response and
therefore, if there might be a critical dose of DCA exposure to
the oesophagus associated with OA development. We have
used both DNA damage induction and NF-jB activation as end
points in these dose–response studies and have investigated the
inherent capacity of oesophageal cells to scavenge ROS as the
MOA behind any non-linearities.
This study may have an important clinical bearing on
patients with GORD either
1. in stratifying patients into high and low cancer risk groups
based on the level of DCA in their refluxate or
2. by identifying a MOA for DCA-induced molecular
abnormalities that is amenable to chemoprevention.
Materials and methods
Cell lines
OE33 cells derived from a Barrett’s related adenocarcinoma were newly
purchased from the European Collection of Cell Cultures (Salisbury, UK) prior
to the beginning of the study. Cells were grown in RPMI 1640 (Life
Technologies, Paisley, UK), supplemented with 1% glutamine and 10% bovine
calf serum (Life Technologies) in a humidified atmosphere of 5% CO2/95% air
at 37C.
Micronucleus assay
For the micronucleus assay, 1–2  105 OE33 cells/ml were seeded into 25 cm2
flasks, 24 h prior to treatment. The OE33 cells were then treated with neutral
pH DCA (Sigma Aldrich, Poole, UK) overnight at various doses for 21 h,
before harvesting. Concurrent with the exposure to DCA, cytochalasin B
(4 lg/ml) was added to block cytokinesis and induce binucleated cells, and the
cells were harvested by trypsin-mediated detachment 21 h later (i.e. 45 h after
cultures were seeded).
Slides were prepared from 100 to 200 ll of the cell pellets using a Cytospin
at 1200 r.p.m. for 8 min. The slides were checked using a light microscope and
air dried before being fixed with 90% methanol at 20C for 10 min (up to
10 slides prepared for each dose). The slides were subsequently stained with
10% Giemsa (BDH, Leicestershire, UK) for 8 min in phosphate buffer at pH
6.8 after being immersed in xylene and allowed to dry. After drying the slides
and mounting the cover slips, the slides were visualized with an Olympus BH2
microscope at 1000 magnification. All slides were scored blind and at least
1000 binucleated cells were counted per dose and assigned as micronucleus
positive or negative. Duplicate cell cultures were established for each dose of
the micronucleus study. The slides obtained from the duplicate cultures were
scored together and the total number of micronuclei in each exposure group (as
a % of the binucleate cell population) was noted. For the dose–response data,
micronucleus data from up to five separate studies were pooled to enhance
the number of events and unpick any subtle changes in dose response. Standard
criteria for selecting micronuclei were used (25). To assess statistical
significance between untreated cells and cells treated with varying doses of
DCA, the Student’s t-test was used to compare micronucleus frequency of the
replicates between treated and untreated cultures.
For the antioxidant supplementation studies, the antioxidants were added to
the OE33 cells 2 h prior to the addition of DCA [final concentrations; 50 lM
for epigallocatechin gallate (EGCG) and 75 lM for resveratrol]. The media
were changed prior to DCA addition to prevent direct chemical interaction in
the media. DCA (200 lM) was added to the cells for 6 h along with
cytochalasin B (4 lg/ml) and the media again changed (but including
cytochalasin B) and further incubation continued for 16 h prior to the cells
being harvested. The antioxidants tested (EGCG and resveratrol) were
dissolved in dimethyl sulphoxide (DMSO) (see below) and DMSO alone
was added to the cells in the negative controls. Fisher’s exact test was used to
assess if there was a significant difference between the numbers of micronuclei
in the DCA-treated cells compared to the DCAþ antioxidant cells.
NF-jB induction
NF-jB activation was assayed by up-regulation of the known NF-jB target
genes (IL-8 and I-jB) in OE33 cells after exposure to varying doses of DCA for
6 h. These genes were chosen to represent DCA-induced NF-jB activity
following previous studies, where they were shown to be common and reliable
markers of NF-jB activity (17). Furthermore, the up-regulation of these genes
Table I. Levels of DCA in the oesophagus (and stomach) of patients with either GORD or Barrett’s oesophagus
Study no. Method Average (DCA) Maximum (DCA) Reference
Ref. no. 23 HPLC on aspirated oesophageal fluid over
a 15-h period. N 5 40 patients
2a and 0 lMa
(2.5 and 5.5 lM)
230a and 280 lMa
(442 and 482 lM)
Nehra et al. (23)
Ref. no. 24 GC on gastric aspirates 3 lM (63 lM) 115 lM (1592 lM) Darragh et al. (24)
Ref. no. 11 HPLC on oesophageal aspirates over
a 17-h period. N 5 80 patients
(35 lM) Kauer et al. (11)
aErosive oesophagitis and Barrett’s oesophagus figures, respectively.
Data show both unconjugated DCA and DCA conjugated to either glycine or taurine (in brackets).
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by DCA was shown to be blocked by several known NF-jB inhibitors,
confirming their NF-jB dependence (data not shown). The DCA dose response
for IL-8 and I-jB expressions was performed in triplicate and representative
expression changes plotted against dose.
Antioxidant supplementation and its effect on NF-jB-dependent gene
expression
OE33 cells were treated with DCA (Sigma, Poole, UK) at a final concentration
of 300 lM for 6 h duration, after they reached 60% confluency. This
concentration of DCA is at the top end of the range of bile acid concentrations
found in patients with Barrett’s oesophagus (23), although the duration of
exposure used was not physiological. For the antioxidant studies, each tested
antioxidant (purchased from Sigma) was administered to the cells overnight
prior to DCA exposure. This differed to the micronucleus study which involved
2-h pre-loading with the antioxidants. The doses of antioxidants were chosen
based either on the literature or following empirical experiments in our
laboratory. The media were subsequently changed and the cells treated with
DCA in fresh medium. The solvent used for the antioxidants (DMSO, ethanol,
water) was administered to the matched negative control flasks. EGCG was
prepared as a 50-mM solution dissolved in DMSO and consequently added to
the cells at final concentrations of 50 and 100 lM. Resveratrol was also
prepared in DMSO as a 50-mM solution and was administered to the cells to
achieve final concentrations of 50 and 75lM. Vitamin C was dissolved in
distilled water to 50 mM and diluted into culture medium to give final
concentrations of 50, 150 and 500 lM. Benzyl isothiocyanate was prepared in
100 mM solution in DMSO and was administered to the cells at final
concentrations of 25 and 40 lM. Vitamin E (a-tocopherol) was prepared in
100 mM solution in ethanol (100%) and was administered to the cells at final
concentrations of 50 and 100 lM.
Replicates of these cell culture experiments were performed to confirm the
results. Real-time PCR was performed on both sets of RNA (twice) giving four
data points per treatment.
RNA extraction and reverse transcription
After incubation with DCA, the OE33 cells were subjected to RNA extraction
using the Midi RNeasy RNA extraction kit (Qiagen, Crawley, Surrey, UK). The
extracted RNA was subsequently DNase treated using a DNA-free kit
(Ambion, Huntingdon, UK). The RNA quantity was assessed by spectropho-
tometry at 260 nm and RNA quality was assessed by RT–PCR using primers
for b-actin DNA.
Real-time PCR
RNA (500 ng) was first reverse transcribed into complementary DNA (cDNA)
using a Retroscript RT kit (Ambion). Real-time PCR was then carried out using
an iCycler PCR machine (BioRad, Hemel Hempstead, UK). cDNA was
amplified and each cDNA batch was aliquoted in triplicate into 96-well plates
using the appropriate PCR primers and the IQ Sybr-green supermix (BioRad).
Primer sequences have previously been published (17). A reference standard
curve was generated for each gene, on each plate, using a diluted cDNA
reference; the relative gene expression levels were then read off this curve. As
the same cDNA reference was used between plates, this allowed normalization
between plates.
One-way analysis of the variance was utilized subsequent to standardization
of the IL-8 and IjB expressions by dividing by b-actin gene expression (a
housekeeping gene). Post hoc multiple comparisons were carried out to
determine if there was a significance difference between these ratios in the
flasks exposed to DCA in isolation and those with different antioxidant
concentrations plus the DCA.
Results
DCA displays a thresholded dose response for DNA damage
Table II shows the raw dose–response data for DCA with
respect to its DNA-damaging ability as measured by the
micronucleus assay. The micronucleus frequency (% binucle-
ated cells with a micronucleus) was determined in several
replicated studies and the data pooled for analysis. Over 37 000
binucleated cells were scored and over 700 micronuclei were
identified. Up to five replicates were available for some doses;
however, the 10- and the 25-lM doses were only performed
once each. The error bars on Figure 1 display the inter-study
variation (as standard deviation) and show good consistency
between replicates. The background micronucleus frequency
shown here is drawn from five different studies looking at
OE33 cells and represents a pooled historical background
figure from over 10 000 binucleate cells.
From the data in Table II, shown graphically in Figure 1,
DCA clearly induced micronuclei (dashed line) in a non-linear
manner in vitro. At low doses of DCA (,100 lM), there was
no significant increase in micronucleus induction over the
untreated controls. However, at doses of 100 lM and higher,
there was a point of inflexion in the curve and significant
increases in chromosome damage (micronucleus induction)
were observed. Indeed, the 100-lM dose is the first dose to
show a significant increase in micronucleus frequency (P 5
0.043). Higher doses of DCA showed highly significant
increases in micronucleus induction over the controls (P ,
0.001 for 125, 150, 200 and 250 lM). It should be noted that
significant toxicity (as measured by a fall in binucleate
frequency—solid line in Figure 1) was associated with DCA
doses .200 lM. We did not test the micronuclei here for
kinetochore status as previously we have shown that DCA
induces chromosome breakage events and not chromosome
copy number changes (i.e. aneuploidy) (14).
DCA induces NF-jB-associated gene expression in a similar
dose-dependent manner to DNA damage
DCA also induced NF-jB activity (as measured by the up-
regulation of two NF-jB target genes, IL-8 and I-jB) at













0 10638 10381 80 49.4 0.7
10 1750 1000 10 36.4 1
25 1512 1000 12 39.8 1.2
50 4010 3000 36 42.8 1.2
75 2162 2000 19 48.0 0.9
100 6702 5000 61 42.7 1.2
125 2799 2000 59 41.7 2.9
150 6240 4000 158 39.1 3.9
200 9975 3000 87 23.1 2.9
250 7438 2000 78 21.2 3.9
300 13704 3000 101 17.9 3.4
This table contains the raw data from the micronucleus studies displayed graphically in Figure 1. The total numbers of mononucleate cells, binucleate cells and
micronucleated binucleate cells are shown. For some DCA doses, data have been pooled from up to five different studies (normally 1000 binucleates are scored per
study). In the case of the negative control, data from more than five studies were available. For the 10- and 25-lM dose, only one set of data were available.
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doses .100 lM (representative expression changes shown in
Figure 2). This dose response is somewhat similar to the
response for DNA damage seen in Figure 1. It was not possible
to replicate all the doses of DCA used in the DNA damage study
in the gene expression study. Furthermore, the data generated by
real-time PCR in Figure 2 are not as amenable to generating dose
responses as compared to the micronucleus assay, partly due to
less power (fewer events) and due to inherent variation in gene
expression between replicates. Hence, statistical significance
was not achieved with any of the DCA doses here, but is seen at
300 lM in the studies shown in Figures 4–6. Nonetheless, the
data generated in Figure 2 bear notable resemblances to the data
in Figure 1, with respect to the doses of DCA capable of causing
biological effects.
The MOA of DCAs dose response involves the generation of
ROS
We have previously shown that DCA-induced chromosome
damage as measured by the micronucleus assay can be
abrogated by pre-exposure of the cells to equimolar amounts
of the antioxidant vitamin C (14). In contrast, we show here
that two other antioxidants (resveratrol and EGCG) do not
block DCAs ability to damage chromosomes. In Figure 3, it is
clear that pre-incubation of the OE33 cells, with resveratrol or
EGCG prior to DCA exposure, has no effect on DCA-induced
micronuclei at the dose (and exposure times) of antioxidant
used here. In order to study the role of ROS in DCA-driven
NF-jB-dependent gene expression, we similarly pre-exposed
OE33 cells to several antioxidants prior to stimulating gene
expression with DCA. Figures 4–6 show the results for ECGC,
resveratrol and vitamin C. All three antioxidants abrogated
DCA-driven gene expression, as measured by IL-8 and I-jB
gene expressions. Two other antioxidants, benzyl isothiocya-
nate and vitamin E (a tocopherol), failed to protect cells from
DCA-induced gene expression changes. EGCG at its higher
dose of 100 lM significantly abrogated both IL-8 and I-jB
expressions (P 5 0.048 and P 5 0.041, respectively).
Resveratrol, at its higher dose of 75 lM, significantly
abrogated the expressions of IL-8 and I-jB (P 5 0.048 and
P 5 0.046, respectively). For vitamin C, significant abrogation
of gene expression occurred at the 150 and 500 lM levels for
both genes (P 5 0.017 and P 5 0.006 for IL-8 and P 5 0.04
and P 5 0.026 for I-jB).
Discussion
We have previously demonstrated that the bile acid DCA is
a clastogen to oesophageal cells (14). We show here for the
first time that DCA damages chromosomes in a non-linear
Fig. 1. The micronucleus frequency data (dashed line) and the binucleate
frequency data (solid line) are plotted against dose of DCA (data from Table II).
The graph shows a clear non-linear response with a no effect level up to 100 lM
DCA and a sharp rise in micronuclei thereafter. Indeed, the 100-lM dose is the
first dose showing a significant rise in micronucleus frequency above the
background (using the t-test on the replicates). Doses of 200 lM or more show
some toxicity as measured by the drop in binucleate frequency.
Fig. 2. Representative IL-8 and I-kB gene expression levels are plotted against
dose of DCA as a measure of NF-kB activity. Relative expression (normalized
against the housekeeper b-actin) is shown. Both IL-8 and I-kB are known
transcriptional targets of NF-kB following DCA exposure (17) and are known
to be NF-kB dependent (through the use of pharmacological inhibitors). Gene
expression increases are evident at the 200- and 300-lM doses, less so at the
100-lM dose. This dose response is somewhat reminiscent of the DNA
damage response in Figure 1.
Fig. 3. The effect of resveratrol and EGCG supplementation on DCA-induced
chromosome damage as measured by the micronucleus assay. Neither of these
antioxidants (at these doses) prevented DCA-driven chromosome damage.
This is in contrast to other studies by ourselves where we have shown that
vitamin C (14) can block DCA-induced DNA damage.
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fashion. Furthermore, a broadly similar dose response was
noted for DCAs ability to induce NF-jB activity (as measured
by up-regulation of two well-known NF-jB-controlled genes).
Interestingly, the data shown here suggest that low doses
(,100 lM) of the bile acid DCA will neither cause DNA
damage nor activate the procarcinogenic signalling molecule
NF-jB in oesophageal cells. Hence, if these in vitro results
were replicated in vivo, it would suggest that the concentration
of damaging bile acids (like DCA) refluxing into the
oesophagus might be useful in stratifying reflux patients into
those at low or high risk of carcinogenesis. Moreover, there
may well be a relationship between the dose of DCA in the
refluxate and the individual risk of OA. This could be clinically
important and may well lead to the development of a biomarker
based on bile acid concentration, to assess individual risk of
cancer development in refluxing patients. The quest for
accurate biomarkers of cancer risk is seen as the ‘holy grail’
in the field of Barrett’s oesophagus as it offers the possibility of
screening the population for high-risk cases without over-
burdening National Health Service endoscopy services.
The available in vivo data on bile acid composition in the
refluxate of GORD patients demonstrate a wide range of
concentrations of bile acids like DCA across patients. This can
range from 0 to 280 lM (23). Our data show here that doses of
100 lM or more are capable of causing DNA damage and NF-
jB-driven gene expression changes. Only a small number of
refluxing patients will have DCA concentrations exceeding
100 lM. Hence, it may be possible that the 10% of Barrett’s
patients who progress to OA are also the patients with the
highest DCA concentrations in their reflux. This possibility is
definitely worthy of close examination in an effort to identify
high-risk cancer patients early when treatment (often surgery) is
still an option.
Other published studies looking at the effect of DCA in vitro
support the conclusions here that 100 lM represents a critical
cut-off concentration in terms of DCA activity. Glinghammar
et al. (26) showed that 100 lM DCA was the lowest dose
capable of inducing NF-jB activity as measured by a luciferase
construct in colorectal cell lines. Song et al. (27) have also
shown conclusively that 100 lM is a key concentration of
DCA for inducing phospho-extracellular signal related kinase
activity and cox-2 expression in SEG-1 cells. Furthermore, Qin
et al. (28) showed that 100 lM DCA had a significant effect in
terms of inducing ROS and VCAM and ICAM expressions in
Fig. 4. The effect of pre-incubation with the tea polyphenol EGCG on DCA-
induced IL-8 and I-kB expressions in OE33 cells. Expression is normalized
against the housekeeper b-actin and also normalized against the negative
control which is given an expression value of 1. EGCG pre-incubation
significantly abrogates DCA-driven NF-kB activity (as measured by IL-8 and
I-kB expressions) at the 100-lM dose.
Fig. 5. The effect of pre-incubation with resveratrol on DCA-induced IL-8 and
I-kB expressions in OE33 cells. Expression is normalized against the
housekeeper b-actin and also normalized against the negative control which is
given an expression value of 1.Resveratrol pre-incubation significantly
abrogates DCA-driven NF-kB activity (as measured by IL-8 and I-kB
expressions) at the 75-lM dose.
Fig. 6. The effect of pre-incubation with vitamin C on DCA-induced IL-8 and I-kB expressions in OE33 cells. Expression is normalized against the housekeeper b-
actin and also normalized against the negative control which is given an expression value of 1. Vitamin C pre-incubation significantly abrogates DCA-driven NF-kB
activity (as measured by IL-8 and I-kB expressions) at the 150- and 500-lM doses.
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endothelial cells. Hence, our data fit well with the published
literature and taken together build a strong case for DCA being
biologically active (in vitro at least) at doses .100 lM.
In mechanistic terms, it is essential to understand how this
dose dependence manifests itself and whether the mechanistic
basis for this effect might be exploitable in therapeutic terms.
We have shown here and elsewhere that the MOA attributable
to DCA-induced biological effects involves the generation of
ROS. Several antioxidants tested by us here and elsewhere (but
interestingly not all) are capable of blocking DCA-driven DNA
damage and NF-jB activity. Presumably, the non-linear dose
response observed for DNA damage and possibly NF-jB
activity is a consequence of a similar non-linear induction of
ROS by DCA. Hence, at low levels of DCA exposure, there are
limited amounts of ROS generated and/or that these levels of
ROS are effectively dealt with by intrinsic antioxidant defences
of the cell (antioxidant nutrients and enzymes such as
superoxide dismutase, catalase and glutathione peroxidase).
At doses of 100 lM or more, these antioxidant defences are
saturated by the ROS generated and hence DCA activity, in
terms of DNA damage and NF-jB activity, is observed.
Therefore, because DCA-driven DNA damage induction and
NF-jB activation involves ROS, and given the fact that some
of the antioxidants were shown here to abrogate these effects in
vitro, there is a strong case for antioxidant supplementation as
a chemopreventative strategy in GORD patients. There is
already excellent evidence that Barrett’s patients intaking diets
rich in antioxidants are protected against adenocarcinoma
development (29,30). However, it is important to take note of
the fact that not all antioxidants performed equally, hence some
antioxidants may be more beneficial than others. Also, the
doses used here vary (50 lM for EGCG, up to 500 lM for
vitamin C) as does the time of incubation prior to DCA
addition (2 h for DNA damage, overnight for NF-jB) and
hence, any lack of effect seen here could be a consequence of
the dosing regime. However, in both DNA damage induction
and NF-jB activation, several antioxidants were protective and
given that each separate study used the same antioxidants and
used the same dosing regime, it was possible to rank each
antioxidant’s efficacy, with vitamin C apparently most ef-
fective, showing here suppression of gene expression changes
and previously being shown by us to prevent DCA-driven
micronuclei (14). Chemoprevention with antioxidants could be
extremely important to GORD patients and patients with
Barrett’s oesophagus in terms of protecting them from OA,
a deadly form of cancer. Coupling a chemoprevention strategy
based on antioxidant supplementation to detailed measurement
of bile acid concentration in gastric juice (with particular
emphasis on DCA) would allow targeting the therapy to those
who particularly need such intervention, on the basis of the
levels of DCA in their refluxate.
Obviously, it is important to bear in mind that we have
shown here data for only one bile acid at neutral pH. In reality,
reflux involves exposure of the oesophagus to dozens of bile
acids and the reflux background may be neutral in pH, weakly
acidic or strongly acidic. Therefore, in order to fully convince
the scientific community of the non-linear response to reflux in
general in the oesophagus, more data are required from other
reflux constituents. However, it is important to point out that
we have previously shown that many of the conjugated bile
acids (plus cholic acid) present in the refluxate do not cause
DNA damage (14). In addition, we showed previously that
acidification of DCA did not alter its DNA-damaging potential
(14). Nonetheless, repeating the experiments presented here
with other potentially active bile acids (like chenodeoxycholic
acid) or with bile acid mixtures, representing those seen in vivo,
would be beneficial. Furthermore, an important caveat to
mention is that the shape of the dose response (Figure 1) may
be influenced by the sensitivity of the assay used (the
micronucleus assay). However, given the large numbers of
cells studied here and the sharp increase in micronucleus
frequency noted at the threshold doses and above, we feel that
we are observing a true biological effect and are not being
influenced by low sensitivity issues.
In conclusion, we have shown here that DCA, a secondary
bile acid linked to several cancers of the GI tract, has a non-
linear dose response for DNA damage as measured by the
micronucleus assay. In addition, it shows a similar non-linear
response for NF-jB activation. In both cases, 100 lM appears
to be the cut-off dose. We further show that the MOA probably
involves the generation of ROS by DCA and that these
deleterious effects can be blocked by some antioxidants. This
offers hope for firstly identifying refluxing patients at highest
risk of cancer development (based on bile acid subtype and
concentration) and further preventing oesophageal cancer
development through antioxidant chemoprevention.
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